ModifiedUnitedHealthcarePolicy CS054NM.D

Airway Clearance Devices (for New Mexico Only)

Defines UnitedHealthcare Community Plan coverage and medical necessity criteria for high-frequency chest wall oscillation (HFCWO) systems and other airway clearance devices for members in New Mexico.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices (for New Mexico Only)

Policy CodePolicy CS054NM.D

Change TypeMaterial revision to medical necessity languagedocumentation added

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionObtain and submit an initial 2-month rental trial documentation demonstrating tolerance and efficacy for HFCWO when requesting coverage.

SourceLink

POLICY UPDATE CHANGES

Updated language pertaining to medical necessity clinical coverage criteria for a high-frequency chest wall oscillation (HFCWO) system.

Added explicit medical record documentation requirements that may be requested to assess whether a member meets clinical criteria for coverage.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

2-monthrequired initial rental trial for HFCWO

Neuromuscular, Bronchiectasis, CFproven conditions

UnprovenOLE/IPV status

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Airway Clearance Devices

inv-01: HFCWO Coverage Criteria — Covered when ALL of the following are met

Covered when ALL of the following are met

HFCWO medical necessity: Member has a diagnosis of neuromuscular disease OR bronchiectasis OR cystic fibrosis.

Document diagnosis with supporting records and relevant ICD-10 codes.

Initial trial requirement: Completion of an initial 2-month rental trial of a high-frequency chest wall oscillation (HFCWO) system that demonstrates individual tolerance and efficacy as documented in the medical record.2-month rental trial

Ongoing coverage for HFCWO requires meeting InterQual criteria; initial rental trial must confirm tolerance and efficacy.

Ongoing use determination: Ongoing medical necessity for continued provision is determined by InterQual Client Defined criteria for Airway or Secretion Clearance Devices (Custom) - UHG and supported by clinical documentation.

Refer to InterQual for specific clinical inclusion/exclusion criteria and documentation expectations.

inv-02: Not Medically Necessary / Unproven — Unproven uses and exclusions

Not covered / considered unproven

Unproven / not medically necessary uses: Use of HFCWO for conditions other than neuromuscular disease, bronchiectasis, or cystic fibrosis; intrapulmonary percussive ventilation (IPV) devices for home use; and combination continuous PEP/continuous high-frequency oscillation with nebulized medication therapy devices (OLE) are considered unproven and not medically necessary due to insufficient quality or consistent evidence.

These uses are classified as unproven/not medically necessary.

inv-03: Coverage determinations and evidence summary — Evidence-informed stance

Coverage stance derived from evidence summaries in these sections

OLE device evidence: Combination continuous PEP and continuous high-frequency oscillation with nebulized medication therapy devices (OLE) lack sufficient quality evidence or consistent findings and are considered unproven/not medically necessary.

Explicit statement in policy based on systematic reviews and prospective study findings.

HFCWO evidence summary: Evidence for HFCWO is mixed: some studies report reductions in hospitalizations, exacerbations, or improved sputum clearance and quality-of-life measures in bronchiectasis and neuromuscular disease cohorts, but many studies are small, nonrandomized, heterogeneous, or low certainty; therefore clinical usefulness requires further investigation.

Summarizes multiple clinical studies and systematic reviews.

inv-04: Coverage-relevant conclusions — Summarized conclusions from evidence/guidelines

Summary of coverage-relevant conclusions from the evidence and guidelines in this section:

Comparative effectiveness of oscillatory devices: There is no clear evidence that oscillatory devices (including HFCWO) are overall superior or inferior to other airway clearance techniques; existing evidence is generally low to very low quality and heterogeneous.

Consider individual preference, adherence, and device-specific contexts; more high-quality trials needed.

OLE clinical signals: Nonrandomized multicenter evidence suggests OLE may reduce postoperative pulmonary complications and resource use in selected high‑risk surgical patients, but RCT-level evidence is lacking to support routine use.

Further well-designed prospective controlled trials required.

IPV evidence and use considerations: IPV shows weak and heterogeneous evidence with some ICU studies reporting reduced ICU length of stay and modest physiologic improvements; routine long‑term home use is not supported by current evidence.

Effectiveness may be setting- and population-specific; document indication and response when used in high-dependency settings.

inv-05: Medical necessity criteria (reference to InterQual) — Policy updates clarifying InterQual reference and documentation expectations

Policy updates clarify medical necessity criteria reference and documentation expectations; specific clinical inclusion/exclusion criteria are defined using InterQual Client Defined criteria.

InterQual as criteria source: Coverage determinations use InterQual Client Defined criteria for Airway or Secretion Clearance Devices (Custom) - UHG for specific clinical inclusion and exclusion criteria.

InterQual criteria drive the detailed clinical decision rules; this policy references InterQual rather than restating all criteria.

Documentation expectations: Medical record documentation that supports medical necessity must be available and may be requested; documentation should include relevant medical history, physical examination, diagnostic test results, and records demonstrating tolerance and efficacy during the initial 2-month rental trial.2-month rental trial documentation

Records must be legible and made available upon request.

Combination continuous positive expiratory pressure, continuous high-frequency oscillation, and nebulized medication therapy devices (sometimes described as combined CPAP/oscillation/nebulization devices) are considered unproven and not medically necessary due to insufficient quality evidence and inconsistent findings. The policy explicitly identifies these combination devices for oscillation and lung expansion (OLE) as not meeting medical necessity standards.

Intrapulmonary percussive ventilation (IPV) devices for home use are classified as unproven and not medically necessary. The evidence does not support routine long-term home use, and routine IPV as an airway clearance therapy for chronic obstructive airway diseases is not supported by sufficiently strong evidence.

Devices combining continuous PEP, continuous high-frequency oscillation, and nebulized medication therapy (often termed OLE devices) are explicitly considered unproven and not medically necessary because available studies are low quality, heterogeneous, and provide inconsistent results regarding clinical benefit.

NICE guidance for cystic fibrosis emphasizes individualized assessment of airway clearance techniques and advises that HFCWO should not be offered for people with cystic fibrosis except in exceptional clinical circumstances decided by the specialist cystic fibrosis team; regular assessment and individualized plans are recommended when selecting ACTs.

Routine use of intrapulmonary percussive ventilation (IPV) as an airway clearance therapy in chronic obstructive airway diseases is not supported by sufficiently strong evidence; home use in particular lacks quality data to justify routine coverage.

Per NICE and the evidence summaries, HFCWO is not recommended as a routine airway clearance technique for people with cystic fibrosis; it should only be considered in exceptional clinical circumstances determined by the specialist CF team.

Overall, HFCWO is considered medically necessary only for members with neuromuscular disease, bronchiectasis, or cystic fibrosis when InterQual criteria are met and an initial 2-month rental trial documents individual tolerance and efficacy. Outside those indications, and for most other populations, HFCWO and OLE devices are considered unproven or not medically necessary because the body of evidence is small, heterogeneous, or of low quality.

OLE devices lack consistent, high-quality evidence of benefit; available trials are small, of low or very low certainty, and do not demonstrate clear superiority for oscillatory combination devices. Consequently, these devices are considered not medically necessary due to insufficient evidence.

Across studies of oscillatory airway clearance techniques, there is no clear evidence that any single oscillatory ACT consistently outperforms others. Choice of device should therefore be individualized based on patient preference, adherence, and clinical response rather than an assumption of inherent superiority.

For patients with cystic fibrosis, evidence reviewed by NICE and summarized in the policy indicates that HFCWO is not routinely recommended; specialist judgement is required to define any exceptional circumstances in which HFCWO might be considered.

Coding and Billing Codes

Applicable HCPCS codesHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0481	Intrapulmonary percussive ventilation system and related accessories.
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each.

Applicable ICD-10 codes (selected examples)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated.
E84.0	Cystic fibrosis with pulmonary manifestations.
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman].
G12.21	Amyotrophic lateral sclerosis
J47.9	Bronchiectasis, uncomplicated.
Z99.11	Dependence on respirator [ventilator] status

Device product codesmixed

BYI	FDA product code referenced for HFCWO devices

inv-19: Cough peak flow (PCF) — threshold value used in considerations

PCF thresholdPeak cough flow (PCF) < 270 L/min

ContextUsed by ATS to identify patients (e.g., DMD) who need assisted cough technologies

Clinical implicationPCF <270 L/min indicates likely need for assisted cough or MI-E per ATS guidance

inv-20: Maximal expiratory pressures — threshold value used in considerations

Maximal expiratory pressure thresholdMaximal expiratory pressures < 60 cm H2O

ContextReferenced by ATS in DMD respiratory care consensus as criterion for assisted cough technologies

Provider Actions, Prior Authorization, and Step Therapy

Prior Authorization

Prior Authorization and Criteria Source

Prior authorization is required for HFCWO systems. UnitedHealthcare may use InterQual® Client Defined (CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG) criteria to make medical necessity determinations. An initial 2-month rental trial is required to establish individual tolerance and efficacy before purchase or ongoing provision is considered medically necessary.

InterQual® Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG

Denial Risk

OLE and IPV Devices — Unproven / Not Medically Necessary

Combination OLE devices (continuous PEP, continuous high-frequency oscillation plus nebulized medication) and intrapulmonary percussive ventilation (IPV) devices for home use are considered unproven and not medically necessary due to insufficient quality evidence or inconsistency of findings.

Medical Necessity and Clinical Considerations

inv-45: DME Medical Necessity — Medical necessity limited to specified conditions when InterQual and 2-month rental trial show benefit

Medical necessity for HFCWO is limited to the following conditions when InterQual criteria are met and a 2-month rental trial shows benefit:

Eligible diagnoses: Member has a documented diagnosis of neuromuscular disease OR bronchiectasis OR cystic fibrosis.

Document diagnosis with supporting records and applicable ICD-10 codes.

Initial rental trial and documented benefit: Completion of an initial 2-month rental trial of HFCWO with documented individual tolerance and clinical benefit in the medical record.2-month trial

Ongoing coverage requires meeting InterQual criteria for continued use.

InterQual confirmation for ongoing coverage:

Rental, Purchase, and Replacement Rules

Equipment	Rule	Notes
High-frequency chest wall oscillation (HFCWO) system	rental	An initial 2-month rental trial is required to confirm individual tolerance and efficacy before ongoing coverage or purchase is determined (refer to InterQual criteria for ongoing use).

Equipment	Allowed Provision Options	Supporting Details / Rationale
High-frequency chest wall oscillation (HFCWO) systems	rental \| purchase	Registry and claims studies of home-use HFCWO exist; policy requires an initial 2-month rental trial to document benefit before determining ongoing coverage or purchase. Continued coverage is subject to InterQual medical necessity criteria.

Equipment	Allowed Provision Options	Notes / Limitations
Intrapulmonary percussive ventilation (IPV)	rental \| purchase \| capped_rental	Evidence often delivered by health professionals and may not generalize to unsupervised home use; routine long-term home use is considered unproven/not medically necessary. Coverage decisions should reflect these limitations.
Other oscillatory airway clearance therapy (ACT) devices (including HFCWO in some settings)	rental \| purchase \| capped_rental	Clinical trial settings and supervised delivery limit generalizability to unsupervised home use; initial rental trials and documentation of benefit are recommended prior to purchase. InterQual criteria guide ongoing coverage determinations.

Equipment	Provision Rule (unspecified / plan-governed)	Guidance
High-frequency chest wall oscillation (HFCWO) systems	unspecified	Rental vs purchase determinations are governed by plan contract terms and InterQual guidance; always verify federal, state, or contractual benefit requirements when making coverage decisions.

inv-53: HFCWO systems — replacement key value (not specified in this policy chunk)

Replacement intervalNot specified in this policy chunk

ActionReplacement/replacement-interval determinations may be governed by plan contract or InterQual guidance (not detailed here)

DocumentationMedical records supporting ongoing need and device performance should be maintained and may be requested

Documentation Requirements and Evidence

Documentation Required

Document tolerance and efficacy during the 2-month rental trial

During the initial 2-month rental trial, document tolerance and efficacy (symptom response, adherence, and any objective utilization changes); further documentation per InterQual is required for ongoing coverage.

Capture trial duration, patient-reported outcomes, and any objective changes in utilization.

Documentation Required

Provide objective utilization and clinical outcome data to support benefit

Provide objective clinical and utilization documentation (hospitalizations, antibiotic use, exacerbation counts, validated patient-reported outcomes) to substantiate that the device provides clinical benefit.

Comparative pre/post metrics strengthen the case for continued coverage.

Documentation Required

Not Covered / Exclusions

Not covered: HFCWO for indications other than neuromuscular disease, bronchiectasis, or cystic fibrosis; intrapulmonary percussive ventilation for home use; and combination CPAP/oscillation/nebulization devices are explicitly listed as not covered because current evidence is insufficient to demonstrate medical necessity.

Not covered: OLE devices (combining continuous PEP, continuous high-frequency oscillation, and nebulized medication therapy) are considered not covered due to insufficient quality and consistency of evidence supporting their use.

Not covered: Routine long-term home use of IPV and routine use of HFCWO for cystic fibrosis (except in exceptional, specialist-determined cases) are not supported by the available evidence and therefore not covered routinely.

This entry is reserved for internal use and does not contain specific coverage text or supporting citations in the provided document excerpts.

Background and Definitions

Background: Airway clearance is impaired in conditions with increased or viscous secretions or ineffective cough (for example, neuromuscular disease, cystic fibrosis, and bronchiectasis). HFCWO devices are external vest-based systems that apply rapid chest wall oscillations to mobilize secretions and augment cough effectiveness; IPV delivers high-frequency bursts of gas via a mouthpiece. Conventional chest physiotherapy (percussion and postural drainage) can be effective but is labor-intensive and may have adherence challenges, which has driven interest in device-based ACTs.

inv-38: Bronchiectasis — definition/key features

DefinitionBronchiectasis: chronic respiratory disease with dilation of airways and recurrent, chronic, or refractory infections confirmed radiographically

Clinical featuresClinically significant bronchiectasis has ≥2 of: cough most days, sputum production most days, or history of exacerbations

Diagnostic methodConfirmed and classified by high-resolution, spiral, or standard CT scan

inv-39: OLE — definition of combination device

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices (for New Mexico Only)

Policy CodePolicy CS054NM.D

Change TypeMaterial revision to medical necessity languagedocumentation added

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionObtain and submit an initial 2-month rental trial documentation demonstrating tolerance and efficacy for HFCWO when requesting coverage.

SourceLink

On This Page

Guideline recommendations relevant to coverage: Guidelines do not identify a single superior ACT. NICE recommends against offering HFCWO for cystic fibrosis except in exceptional clinical circumstances; ATS recommends assisted cough/MI-E for DMD patients with PCF < 270 L/min or maximal expiratory pressures < 60 cm H2O.PCF < 270 L/min OR maximal expiratory pressures < 60 cm H2O

Device selection should be individualized and guided by specialist teams.

Clinical implicationValues <60 cm H2O support use of assisted cough/MI-E in patients with ineffective cough

Combination OLE devices: not medically necessary

IPV devices for home use: not medically necessary

Documentation Required

Documentation-Related Denials

Medical records documentation may be requested to evaluate whether the member meets clinical criteria. Incomplete, illegible, or insufficient documentation that does not fully support medical necessity may result in denial of the request.

Denial triggers include lack of documented 2-month rental trial, use for non-covered conditions, or insufficient medical record documentation

Documentation Required

Medical Records Required for Reviews

The patient's medical record must contain documentation that fully supports the medical necessity for the requested device. Required elements include relevant medical history, physical examination findings, results of pertinent diagnostic tests or procedures, and objective utilization data where applicable. Records must be legible and made available upon request.

History, exam, and diagnostic test results
Objective utilization data (e.g., frequency of exacerbations, hospitalizations, antibiotic use)
Legible chart notes and device trial documentation

Documentation Required

Supporting Clinical and Utilization Documentation

Support ongoing coverage decisions with objective clinical and utilization documentation demonstrating benefit during the 2-month rental trial and thereafter. Document selection rationale, therapy setting, measured outcomes (e.g., exacerbation frequency, hospitalizations, patient-reported ability to clear secretions), and how the device compares to or complements standard ACTs.

Objective outcomes (exacerbations, hospitalizations, antibiotic use)
Patient-reported outcomes and tolerance
Documentation of setting and selection rationale

Documentation Required

Document Outcomes and Selection

Document the rationale for selecting HFCWO or alternative devices, the clinical setting (home versus facility), outcomes measured during the rental trial, and any changes to ACTs. This documentation should show that the device provides benefit over standard airway clearance techniques for that individual.

Patient selection and specialist input (if applicable)
Measured outcomes during 2-month trial
Comparison to prior standard ACTs

Step Therapy

Step Requirement — Initial Rental Trial

The initial 2-month rental trial functions as a required step to establish tolerance and efficacy prior to purchase or continued provision. Failure to complete or document this trial may lead to a denial.

2-month rental trial required before ongoing coverage or purchase

Step Therapy

Consider Step Therapy Using Established ACTs Prior to HFCWO/Combination Devices

Before escalating to HFCWO or combination devices, consider and document trials of established airway clearance techniques (ACTs) such as active cycle of breathing techniques (ACBT), positive expiratory pressure (PEP)/O-PEP, postural drainage and percussion, and individualized ACT plans. Use of standard, less complex ACTs should be attempted and documented when clinically appropriate.

Try standard ACTs first (ACBT, PEP/O-PEP, postural drainage/percussion)
Document attempts and response to standard ACTs prior to device escalation

Note

Sequencing vs Other Airway Clearance Techniques

Sequencing and selection of airway clearance techniques should be individualized. Regularly assess effectiveness and modify technique or choose a different ACT if needed. Specialist input (e.g., cystic fibrosis team) should be obtained for exceptional circumstances where HFCWO may be considered despite general guidance against routine use.

Individualized assessment and regular reassessment of ACT effectiveness
Specialist team decision for exceptional HFCWO use in cystic fibrosis per NICE guidance

InterQual Client Defined Airway or Secretion Clearance Devices criteria must be met for ongoing coverage beyond the rental trial; clinical documentation must support that HFCWO is the physician's chosen external chest manipulation to enhance mucus transport.

Refer to InterQual for specific clinical details (e.g., prior therapy trials, functional impairment).

inv-46: Suggested medical necessity documentation for HFCWO — require demonstration of likely benefit given limited high-quality data

Suggested documentation to demonstrate likely benefit given limited high-quality data:

Clinical history and prior treatments: Document chronic hypersecretive airway disease (e.g., bronchiectasis, neuromuscular disease) with objective evidence of frequent exacerbations or hospitalizations despite standard airway clearance measures and trials of alternative established ACTs as appropriate.

Provide counts of exacerbations/hospitalizations and documentation of prior ACT use and response.

Objective baseline measures: Provide objective baseline measures (e.g., exacerbation frequency, hospital days, sputum production, validated patient-reported outcomes) to allow pre/post comparison during and after the rental trial.

Claims or registry data alone are insufficient; include clinical notes and objective utilization data when possible.

Documented trial outcomes: Document tolerance, adherence, and measurable clinical response during the initial 2-month rental trial (for example, reductions in exacerbations, antibiotic use, or hospital days; or patient-reported improvement in sputum clearance or quality of life).2-month trial documentation

Medical records must be legible and made available upon request.

inv-47: DME medical necessity considerations — device-specific considerations from guidelines and evidence

Device-specific considerations based on guideline excerpts and evidence:

HFCWO in cystic fibrosis: HFCWO is generally not recommended as a routine airway clearance technique for people with cystic fibrosis and should be offered only in exceptional clinical circumstances determined by the specialist cystic fibrosis team.

NICE guidance indicates HFCWO is not as effective as other ACTs; specialist team decision required for exceptions.

Assisted cough / MI-E in neuromuscular disease: For patients with neuromuscular disease (e.g., DMD) consider mechanical insufflation-exsufflation (MI-E) and assisted cough technologies when clinical history suggests difficulty clearing secretions or when PCF < 270 L/min or maximal expiratory pressures < 60 cm H2O.PCF < 270 L/min OR maximal expiratory pressures < 60 cm H2O

Supported by ATS consensus guidance.

IPV considerations: IPV may be considered in ICU or high-dependency settings where some evidence suggests reductions in ICU length of stay and modest physiologic improvements; routine home use is not supported by current evidence.

When used, document indication, delivered therapy, and clinical response metrics.

inv-48: DME medical necessity reference — InterQual Client Defined criteria and clinician documentation support determinations

Coverage is determined using the InterQual Client Defined Airway or Secretion Clearance Devices criteria and supported by clinician documentation:

InterQual-based determination: Coverage determinations should reference InterQual Client Defined Airway or Secretion Clearance Devices (Custom) - UHG for the detailed clinical decision rules used to support medical necessity.

InterQual replaces prior referenced custom criteria title per policy update.

Physician documentation of device choice: Physician documents that external chest manipulation (HFCWO) is the chosen treatment to enhance mucus transport for the patient and provides supporting clinical rationale and objective measures as available.

Submit supporting medical records with prior authorization or coverage request; records must be legible and available upon request.

Document device use and outcomes in clinical notes (examples: perioperative/ICU)

Include clinical notes that demonstrate actual device use and observed outcomes, with examples such as perioperative or ICU indications, delivered therapy (OLE, IPV, HFCWO), and resulting clinical measures.

For perioperative/ICU use, document indication (e.g., high-risk surgery), therapy delivered, and response metrics (PPCs, ventilator time, length of stay).

Documentation Required

Include and be ready to submit medical history, exam, and diagnostic test results with requests

Submit supporting medical records with prior authorization or coverage requests; records may be requested to verify that the member meets clinical criteria and must include medical history, physical exam, and pertinent diagnostic test results.

Maintain legible records and make them available upon request to facilitate review.

DefinitionOLE: Combination device integrating continuous positive expiratory pressure (PEP), continuous high-frequency oscillation, and nebulized medication therapy for oscillation and lung expansion

Coverage stanceConsidered unproven and not medically necessary due to insufficient quality evidence or consistency of findings

Evidence noteSystematic reviews found low-to-very-low quality evidence and no clear advantage over other ACTs

inv-40: HFCWO — definition of device

DefinitionHFCWO: external vest/device that applies rapid, high-frequency oscillations or compression to the chest wall to mobilize airway secretions and promote bronchial drainage

IndicationIndicated when external chest manipulation is the physician's chosen treatment to enhance mucus transport

Product referenceFDA product code referenced for HFCWO devices: BYI

inv-41: OLE — alternate entry/definition

Alternate definitionOLE (alternate): Oscillation and lung expansion therapy combining continuous high-frequency oscillation with continuous positive expiratory pressure, used in some perioperative and high-risk settings

Evidence noteNonrandomized multicenter data suggest possible reductions in postoperative pulmonary complications but RCT-level evidence is lacking

Policy implicationOLE devices are treated as unproven/not medically necessary absent stronger evidence

inv-42: PPCs — postoperative pulmonary complications definition

DefinitionPostoperative pulmonary complications (PPCs): complications such as prolonged ventilation, need for high-level respiratory support, pneumonia, and ICU readmission

Use in studiesPPCs used as outcome measures in perioperative and critical-care studies evaluating oscillatory therapies (e.g., OLE)

DocumentationWhen used to justify device use in perioperative settings, clinical notes should document indication and measured PPC outcomes

inv-43: PCF — peak cough flow threshold reference

Threshold referencePCF < 270 L/min cited by ATS as criterion for assisted cough technologies (e.g., MI-E) in DMD patients

Clinical applicationUsed to determine need for assisted cough interventions to prevent atelectasis and pneumonia

Guideline sourceAmerican Thoracic Society consensus statement referenced in policy

inv-44: HFCWO — alternate definition entry

Definition (alternate)HFCWO (alternate entry): High-frequency chest wall compression/oscillation systems are external vest-based devices delivering oscillatory compression to the chest wall to promote airway clearance

Indication noteIntended to improve bronchial drainage when external chest manipulation is the chosen therapy

Regulatory referenceProduct information and FDA product code BYI cited for device details